Spackman expects to climb out of the red in 1Q

Spackman expects to climb out of the red in 1Q

By: 
Jude Chan
10/04/17, 05:32 pm

SINGAPORE (April 10): Spackman Entertainment Group on Monday issued a positive profit guidance for the first quarter ended March 31.

Based on a preliminary review of its first quarter results, Spackman says it expects to report a net profit for 1Q17, reversing out of a net loss reported a year ago.

The turnaround and results improvement is mainly attributed to the revenue and earnings recognition from the film, “Master”. The film was produced by Spackman’s wholly-owned subsidiary, Zip Cinema Co.

Advertisement

Spackman also received production revenue from its upcoming movie, “Golden Slumber”.

In addition, Spackman had disposed of its loss-making subsidiary, Opus Pictures, in August.

“Without this loss-making entity, the Group expects to reduce its fixed overheads and operating expenses significantly,” Spackman said in a filing to SGX.

Shares of Spackman closed 0.1 cent lower at 17.6 cents on Monday.

sentifi.com

Sentifi - The Edge Markets Singapore - Top themes and market

Ryobi Kiso reverses out the red in FY2017 on absence of one-off losses

SINGAPORE (Aug 23): Ryobi Kiso Holdings posted earnings of $0.8 million for the full year ended June, swinging out from losses of $11.4 million a year ago. This was mainly due to the absence of a one-off items which amounted to other losses of $13.9 million a year ago. These comprised the one-off unrecoverable progress claim of $7.4 million that was written off, and the one-off impairment loss of goodwill of $5.6 million in relation to its Australia subsidiaries in FY2016. Revenue fell 24.2% to $144.8 million in FY2017, from $191.0 million a year ago. Revenue from bored piling operati....
Read More >>

iX Biopharma net losses for FY17 narrow to $7.4 mil

SINGAPORE (Aug 23): iX Biopharma, the specialty pharmaceutical company, reported net losses for FY17 ended June narrowed to $7.4 million from losses of $7.7 million a year ago. Revenue rose 10% to $6.4 million. The group currently derives its main source of revenue from the chemical analysis business which saw an 11% rise to $6.3 million from $5.7 million. Revenue from specialty pharmaceutical fell 52% to $49,000 from $103,000. Despite increased activities, iX Biopharma says expenses remained well-managed. For the full financial year, R&D expenses came in at $4.81 million in FY17 ....
Read More >>

AusGroup says AMJV awarded extension of works on Ichthys Project Onshore LNG Facilities worth $178 mil

SINGAPORE (Aug 23): AusGroup today announced that AMJV has been awarded an extension of works on the INPEX-operated Ichthys LNG Project by JKC Australia LNG worth A$165 million ($177.9 million). See: AusGroup subsidiary wins contract for INPEX-operated Ichthys project AMJV is a joint venture between AGC Industries, a subsidiary of AusGroup, and Meisei Industrial. The scope of work for subcontract that was initially awarded in 2014 has been increased to include further painting, surface protection, fireproofing and insulation works for the onshore facilities near Darwin, Australia. ....
Read More >>